AlphAIAlphAI — Financial news for AI agents
investing.comSEP 112 min read$STIM

Neuronetics stock gains after B.Riley initiates coverage at Buy

Neuronetics Inc (STIM) shares rose 3.5% after B.Riley initiated coverage with a Buy rating and $5.00 price target, citing potential earnings growth from the Greenbrook acquisition and a shift in interventional psychiatry. The analyst sees 70% upside from current levels, noting STIM trades at a lower multiple than peers.

Original reporting
investing.com
Published Sep 11, 2026, 1:31 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 11, 2026, 1:38 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefMarket movers
Primary signal
$STIM
Bullish
high confidence
Mentioned
$STIM
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$STIMBullishHigh
01

Why it matters

Coverage upgrade could attract institutional interest and support price appreciation.

02

Market read

Analyst initiation provides fresh catalyst for a small‑cap med‑tech stock.

03

What to watch

Execution risk of scaling Greenbrook acquisition and payer reimbursement timelines.

Relevance 7/10Novelty 7/10Timing: post‑market Friday

Background

Neuronetics recently acquired Greenbrook and reset management; analyst cites growth potential.

Company-level read

Ticker impact

$STIMBullishHigh confidence
Context

B.Riley initiated coverage on Neuronetics with a Buy rating and $5.00 price target, driving a 3.5% share rise.

Expected impact

Potential further upside of up to 7% if target is validated.

Evidence & confidence

Buy rating and sizable upside target provide a clear trading catalyst.

Market effects

Sector

May boost sentiment in the interventional psychiatry and medical device sector.

Regional

Limited to U.S. listed med‑tech stocks.

Global

Low; primarily affects niche neuro‑stimulation market.

Counterpoint

What could challenge this read

Target may be optimistic given early stage of psychedelic integration.

Key entities

  • Company
    Neuronetics Inc

    NASDAQ‑listed neuro‑stimulation device maker (STIM).

  • Research Firm
    B.Riley

    Equity research boutique initiating coverage.

Read at source← All news

Related articles

AUG 18
$STIMMedAI 8/10

Neuronetics (STIM) Q2 2026 Earnings Call Transcript

Neuronetics (STIM) reported Q2 2026 revenue of $41.6M, up 9.1% YoY. Greenbrook revenue grew 16.8% YoY, while NeuroStar revenue fell 2.7% YoY. Net loss narrowed to $3.4M. Full-year revenue guidance was set at $160M-$164M, with gross margin guidance raised to 48%-50%. The company expanded NeuroStar acquisition options and integrated AI into operations. Management highlighted growth opportunities in psychedelic-based therapies and strategic collaborations.

fool.com6 min
AUG 13
Med

Neuronetics, Inc. Q2 2026 Earnings Call Summary

Neuronetics reported Q2 2026 progress on its NeuroStar commercial shift to hybrid capital purchase and lease options, with 17% YoY growth at Greenbrook clinics and a 10% utilization increase in active NeuroStar accounts. Management expects choppier H2 2026 revenue, raised full-year gross margin guidance to 48%-50%, and cut operating expense guidance by $5M.

yahoo.com5 min
AUG 13
$STIMMedAI 8/10

Neuronetics Q2 Earnings Call Highlights

Neuronetics (NASDAQ:STIM) reported Q2 Worldwide NeuroStar revenue of $14.7M, down 2.7% YoY, with capital revenue up and treatment-session revenue down. The company expanded NeuroStar purchase and leasing options, expects no further material inventory reduction in H2, and plans to report NeuroStar as a single revenue line. Gross margin rose to 61.1% and 2026 guidance was narrowed to $160M-$164M.

yahoo.com6 min
AUG 11
$STIMHighAI 8/10

Why is Neuronetics stock surging today?

Neuronetics shares rose about 24% in pre-open after the company reported Q2 2026 results that beat Wall Street on revenue and EPS. Revenue was $41.6M (+9.1% YoY). Net loss narrowed to $3.4M, or -$0.05/share, versus -$10.1M and -$0.15/share a year earlier. Greenbrook revenue grew to $26.9M (+16.8%).

investing.com3 min